Related Experiment Video
Updated: Mar 20, 2026
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Targeted Mesoporous Silica Nanocarriers in Oncology
Alejandro Baeza1, Maria Vallet-Regi1
1Centro de Investigacion Biomedica en Red de Bioingenieria, Biomateriales y Nanomedicina (CIBER- BBN), Madrid, Spain.
Background:
Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population. The development of nanocarriers in oncology has provided a new hope in the fight against this terrible disease.
Objective:
Among the different types of nanoparticles which have been reported in the scientific literature, mesoporous silica nanoparticles (MSNs) are very promising materials due to their inherent properties such as high loading capacity of many different drugs, excellent biocompatibility and easy functionalization.
Results:
This review presents the current state of the art related to the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on targeted MSN able to selectively destroy tumoral cells, reducing the side damage in healthy ones, and the basic principles of targeting tumoral tissues and cells.
Conclusions:
MSNs constitute a promising nanomaterial for drug delivery applications in antitumoral therapy as a consequence of its unique properties such as excellent biocompatibility, high loading capacity, robustness, easy production and existence of multiple strategies for their functionalization with a myriad of bio-organic moieties. In the coming years, the clever application of this material would provide novel alternatives for the treatment of this complex disease.
Insights
Mesoporous silica nanoparticles (MSNs) offer a promising approach for cancer therapy due to their drug-loading capacity and biocompatibility. Targeted MSNs can selectively destroy tumor cells, minimizing damage to healthy tissues.
Area of Science:
- Nanotechnology
- Oncology
- Materials Science
Background:
- Cancer is a leading global cause of death, with increasing prevalence due to aging populations.
- Nanocarriers represent a hopeful advancement in cancer treatment strategies.
Purpose of the Study:
- To review the development of mesoporous silica nanocarriers (MSNs) for antitumoral therapy.
- To highlight targeted MSNs for selective tumor cell destruction and reduced side effects.
- To discuss the principles of targeting tumor tissues and cells.
Main Methods:
- Review of scientific literature on mesoporous silica nanoparticles (MSNs).
- Focus on MSN properties relevant to drug delivery and cancer therapy.
- Analysis of targeting strategies for tumor tissues and cells.
Main Results:
- Mesoporous silica nanoparticles (MSNs) exhibit high drug-loading capacity, excellent biocompatibility, and facile functionalization.
- Targeted MSNs demonstrate potential for selective destruction of tumor cells.
- Reduced damage to healthy tissues is a key advantage of targeted MSN approaches.
Conclusions:
- MSNs are a promising nanomaterial for drug delivery in antitumoral therapy.
- Unique properties of MSNs include biocompatibility, high loading capacity, and functionalization potential.
- Future applications of MSNs may offer novel cancer treatment alternatives.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...